Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
Latest posts by Hippocratic Post (see all)
- Breaking the ice for men’s mental health - 26th December 2025
- New bowel cancer test for early detection - 26th December 2025
- New method accelerates resistance testing in UTIs - 26th December 2025